Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

MCL1 Inhibitors in Multiple Myeloma

Karin Vanderkerken, PhD, Kim De Veirman, Ken Maes, Eline Menu, PhD, Elke De Bruyne, PhD

Blood (2019) 134 (Supplement_1): SCI-12.

https://doi.org/10.1182/blood-2019-121104

Published: 2019

Journal Articles

Receptor Tyrosine Kinase AXL: A Potential Strategy to Counter Immune Suppression and Dormancy in Multiple Myeloma

Kim De Veirman, Siyang Yan, Ken Maes, Nathan De Beule, MD, Sylvia Faict, MSc, Elke De Bruyne, PhD, Eline Menu, PhD, Karin Vanderkerken, PhD

Blood (2019) 134 (Supplement_1): 4335.

https://doi.org/10.1182/blood-2019-126834

Published: 2019

Journal Articles

The Exosomal Transfer of Acid Sphingomyelinase Contributes to Drug Resistance in Multiple Myeloma

Inge Oudaert, MSc, Sylvia Faict, MSc, Ludovic D'Auria, PhD, Jonas Dehairs, PhD, Ken Maes, Philip Vlummens, MD, Lotte Jacobs, BSc, Kim De Veirman, Elke De Bruyne, PhD, Karel Fostier, MD, Isabelle Vande Broek, MD PhD, Rik Schots, Karin Vanderkerken, PhD, Johannes V. Swinnen, PhD, Eline Menu, PhD

Blood (2019) 134 (Supplement_1): 3058.

https://doi.org/10.1182/blood-2019-122857

Published: 2019

Journal Articles

Exosomes Play a Key Role in Multiple Myeloma Bone Disease and Tumor Development

Sylvia Faict, MD, Josephine Muller, PhD, Kim De Veirman, PhD, Ken Maes, Elke De Bruyne, PhD, Rik Schots, Jo Caers, MD PhD, Karin Vanderkerken, PhD, Eline Menu, PhD

Blood (2018) 132 (Supplement 1): 4484.

https://doi.org/10.1182/blood-2018-99-112428

Published: 2018

Journal Articles

Histone Methyltransferases G9a and GLP; Identification and Validation of Novel Therapeutic Targets for Multiple Myeloma Treatment

Eva De Smedt, Julie Devin, Hui Liu, Anke Maes, Ken Maes, Kim De Veirman, Eline Menu, PhD, Karin Vanderkerken, PhD, Jerome Moreaux, PhD, Elke De Bruyne, PhD

Blood (2017) 130 (Supplement 1): 4356.

https://doi.org/10.1182/blood.V130.Suppl_1.4356.4356

Published: 2017

Journal Articles

The Anaphase Promoting Complex/Cyclosome: A New Promising Target in Mantle Cell Lymphoma and Diffuse Large B Cell Lymphoma

Anke Maes, Eva De Smedt, Kim De Veirman, Ken Maes, Eline Menu, PhD, Els Van Valckenborgh, PhD, Karin Vanderkerken, PhD, Elke De Bruyne, PhD

Blood (2017) 130 (Supplement 1): 2757.

https://doi.org/10.1182/blood.V130.Suppl_1.2757.2757

Published: 2017

Journal Articles

Targeting S100A9 Interactions in the Multiple Myeloma Bone Marrow Environment Reduces Angiogenesis and Tumor Growth

Kim De Veirman, PhD, Els Van Valckenborgh, PhD, Nathan De Beule, MD, Hendrik De Raeve, Ken Maes, PhD, Elke De Bruyne, PhD, Eline Menu, PhD, Karin Vanderkerken, PhD

Blood (2016) 128 (22): 3248.

https://doi.org/10.1182/blood.V128.22.3248.3248

Published: 2016

Journal Articles

The Crosstalk Between Leptin Receptor Activation and iNKT Mediated Anti-Tumor Immunity in Multiple Myeloma

Mérédis Favreau, PhDstudent, Eline Menu, PhD, Karin Vanderkerken, PhD, Sylvia Faict, MD, Ken Maes, PhD, Els Van Valckenborgh, PhD, Elke De Bruyne, PhD, Srinath Govindarajan, PhDstudent, Michael Drennan, PhD, Xavier Leleu, Lennart Zabeau, PhD, Jan Tavernier, PhD, Koen Venken, PhD, Dirk Elewaut, MD PhD

Blood (2016) 128 (22): 2075.

https://doi.org/10.1182/blood.V128.22.2075.2075

Published: 2016

Journal Articles

The Src Inhibitor AZD0530 Prevents the Development of Osteolytic Bone Disease in Multiple Myeloma

Roy Heusschen, PhD, Joséphine Muller, MSc, Marilène Binsfeld, MSc, Erwan Plougonven, PhD, Nadia Mahli, BSc, Geert Carmeliet, MD PhD, Angélique Léonard, PhD, Martine Cohen-Solal, MD PhD, Karin Vanderkerken, PhD, Yves Beguin, MD PhD, Eline Menu, PhD, Jo Caers, MD PhD

Blood (2015) 126 (23): 3018.

https://doi.org/10.1182/blood.V126.23.3018.3018

Published: 2015

Journal Articles

The in vivo Transcriptional Response Towards Epigenetic Modulating Agents in Multiple Myeloma

Ken Maes, Eva De Smedt, Kassambara Alboukadel, PhD, Dirk Hose, MD PhD, Anja Seckinger, MD PhD, Els Van Valckenborgh, PhD, Eline Menu, PhD, Bernard Klein, MD PhD, Karin Vanderkerken, PhD, Jerome Moreaux, PhD, Elke De Bruyne, PhD

Blood (2014) 124 (21): 3375.

https://doi.org/10.1182/blood.V124.21.3375.3375

Published: 2014

Journal Articles

Targeting the Anaphase Promoting Complex/Cyclosome (APC/C) in Multiple Myeloma

Susanne Lub, Anke Maes, Ken Maes, Kim De Veirman, Xavier Leleu, MD PhD, Eline Menu, PhD, Elke De Bruyne, PhD, Karin Vanderkerken, PhD, Els Van Valckenborgh, PhD

Blood (2014) 124 (21): 2097.

https://doi.org/10.1182/blood.V124.21.2097.2097

Published: 2014

Journal Articles

Myeloid Derived Suppressor Cell Mediated AMPK Activation Regulates Multiple Myeloma Cell Survival

Kim De Veirman, Jo A. Van Ginderachter, Ivan Van Riet, Nathan De Beule, Susanne Lub, Eline Menu, PhD, Elke De Bruyne, PhD, Karin Vanderkerken, PhD, Els Van Valckenborgh, PhD

Blood (2014) 124 (21): 2009.

https://doi.org/10.1182/blood.V124.21.2009.2009

Published: 2014

Journal Articles

Bone Marrow Stromal Cell-Derived Exosomes Facilitate Multiple Myeloma Cell Survival Through Inhibition Of The JNK Pathway

Jinheng Wang, An Hendrix, PhD, Elke De Bruyne, PhD, Els Van Valckenborgh, PhD, Eddy Himpe, Nathan De Beule, MD, Olivier De Wever, PhD, Karin Vanderkerken, Eline Menu, PhD

Blood (2013) 122 (21): 679.

https://doi.org/10.1182/blood.V122.21.679.679

Published: 2013

Journal Articles

Dll1/Notch Interaction Contributes to a Decreased Sensitivity of Myeloma Cells to Bortezomib

Dehui Xu, Jingsong Hu, Elke De Bruyne, PhD, Eline Menu, PhD, Rik Schots, MD, Karin Vanderkerken, PhD, Els Van Valckenborgh, PhD

Blood (2012) 120 (21): 1840.

https://doi.org/10.1182/blood.V120.21.1840.1840

Published: 2012

Journal Articles

The DNA Methyltransferase Inhibitor Decitabine Induces DNA Damage, Cell Cycle Arrest and Apoptosis in Multiple Myeloma

Ken Maes, Miguel Lemaire, Jordan Gauthier, Hendrik De Raeve, Eline Menu, PhD, Els Van Valckenborgh, PhD, Helena Jernberg Wiklund, PhD, Karin Vanderkerken, PhD, Elke De Bruyne, PhD

Blood (2012) 120 (21): 1833.

https://doi.org/10.1182/blood.V120.21.1833.1833

Published: 2012

Journal Articles

Preclinical Evaluation of Invariant Natural Killer T-Cells in the 5T33 Multiple Myeloma Model

Haneen Nur, Sandrine Aspeslagh, PhD, Els Van Valckenborgh, PhD, Elke De Bruyne, PhD, Dirk Elewaut, MD, PhD, Karin Vanderkerken, PhD, Eline Menu, PhD

Blood (2012) 120 (21): 938.

https://doi.org/10.1182/blood.V120.21.938.938

Published: 2012

Journal Articles

Combination of the IGF-1 Receptor Inhibitor Picropodophylin and the BH3 Mimetic ABT-737 Has Synergistic Anti-Myeloma Activity

Liesbeth Bieghs, Ken Maes, Els Van Valckenborgh, PhD, Eline Menu, PhD, Hans Erik Johnsen, Mette Nyegaard, PhD, Helena Jernberg Wiklund, PhD, Karin Vanderkerken, PhD, Elke De Bruyne, PhD

Blood (2012) 120 (21): 4010.

https://doi.org/10.1182/blood.V120.21.4010.4010

Published: 2012

Journal Articles

Targeting CDK4/CDK6 Impairs Osteoclast Progenitor Pool Expansion and Blocks Osteolytic Lesion Development in Multiple Myeloma.

Rentian Feng, PhD, Xiangao Huang, PhD, Les Coulton, PhD, Hendrik De Raeve, MD, Maurizio DiLiberto, PhD, Scott Ely, MD, MPH, Guozhi Xiao, PhD, Min Luo, MD, Eline Menu, PhD, Peter Croucher, MD, G. David Roodman, MD, PhD, Karin Vanderkerken, MD, Selina Chen-Kiang, PhD, Suzanne Lentzsch, MD, PhD

Blood (2009) 114 (22): 298.

https://doi.org/10.1182/blood.V114.22.298.298

Published: 2009

Journal Articles

Targeting CDK4/6 and the Cell Cycle in Combination with Bortezomib in the 5T33MM Myeloma Model.

Eline Menu, PhD, Josefina Garcia, Ph.D., Xiangao Huang, Ph.D., Maurizio Di Liberto, Ph.D., Peter Toogood, Ph.D., Isan Chen, M.D., Karin Vanderkerken, Ph.D., Selina Chen-Kiang, Ph.D.

Blood (2007) 110 (11): 254.

https://doi.org/10.1182/blood.V110.11.254.254

Published: 2007

Journal Articles

Regulation of Bim Expression by IGF-1 in the 5T33MM Murine Model for Multiple Myeloma.

Elke De Bruyne, Tomas Bos, Sarah Deleu, Peter Atadja, PhD, Eline Menu, PhD, Els Van Valckenborgh, PhD, Ben Van Camp, MD, PhD, Karin Vanderkerken, PhD

Blood (2007) 110 (11): 3512.

https://doi.org/10.1182/blood.V110.11.3512.3512

Published: 2007

NARROW

MCL1 Inhibitors in Multiple Myeloma

Receptor Tyrosine Kinase AXL: A Potential Strategy to Counter Immune Suppression and Dormancy in Multiple Myeloma

The Exosomal Transfer of Acid Sphingomyelinase Contributes to Drug Resistance in Multiple Myeloma

Exosomes Play a Key Role in Multiple Myeloma Bone Disease and Tumor Development

Histone Methyltransferases G9a and GLP; Identification and Validation of Novel Therapeutic Targets for Multiple Myeloma Treatment

The Anaphase Promoting Complex/Cyclosome: A New Promising Target in Mantle Cell Lymphoma and Diffuse Large B Cell Lymphoma

Targeting S100A9 Interactions in the Multiple Myeloma Bone Marrow Environment Reduces Angiogenesis and Tumor Growth

The Crosstalk Between Leptin Receptor Activation and iNKT Mediated Anti-Tumor Immunity in Multiple Myeloma

The Src Inhibitor AZD0530 Prevents the Development of Osteolytic Bone Disease in Multiple Myeloma

The in vivo Transcriptional Response Towards Epigenetic Modulating Agents in Multiple Myeloma

Targeting the Anaphase Promoting Complex/Cyclosome (APC/C) in Multiple Myeloma

Myeloid Derived Suppressor Cell Mediated AMPK Activation Regulates Multiple Myeloma Cell Survival

Bone Marrow Stromal Cell-Derived Exosomes Facilitate Multiple Myeloma Cell Survival Through Inhibition Of The JNK Pathway

Dll1/Notch Interaction Contributes to a Decreased Sensitivity of Myeloma Cells to Bortezomib

The DNA Methyltransferase Inhibitor Decitabine Induces DNA Damage, Cell Cycle Arrest and Apoptosis in Multiple Myeloma

Preclinical Evaluation of Invariant Natural Killer T-Cells in the 5T33 Multiple Myeloma Model

Combination of the IGF-1 Receptor Inhibitor Picropodophylin and the BH3 Mimetic ABT-737 Has Synergistic Anti-Myeloma Activity

Targeting CDK4/CDK6 Impairs Osteoclast Progenitor Pool Expansion and Blocks Osteolytic Lesion Development in Multiple Myeloma.

Targeting CDK4/6 and the Cell Cycle in Combination with Bortezomib in the 5T33MM Myeloma Model.

Regulation of Bim Expression by IGF-1 in the 5T33MM Murine Model for Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only